Patterns of Care and Utilization of Radiation for Women With Good-Risk Ductal Carcinoma In Situ: A National Cancer Database Analysis

被引:0
作者
Silver, Benjamin [1 ]
Mattessich, Sarah [1 ]
Yacoub, Irini [1 ]
Rhee, Brian [1 ]
Schreiber, David [2 ]
机构
[1] SUNY, Downstate Med Ctr, Radiat Oncol, Brooklyn, NY 11201 USA
[2] Summit Med Grp, Radiat Oncol, Berkeley Hts, NJ USA
关键词
national cancer database and seer analyses; practice patterns; radiation fractionation; breast cancer management; ductal carcinoma in-situ; BREAST-CONSERVING SURGERY; RANDOMIZED-TRIAL; LOCAL RECURRENCE; RADIOTHERAPY; IRRADIATION; TAMOXIFEN; LUMPECTOMY; PHASE-3; OLDER;
D O I
10.7759/cureus.28223
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose/objective(s) Lumpectomy followed by whole-breast radiation therapy (WBRT) provides a 50% recurrence rate reduction in ductal carcinoma in situ (DCIS) patients when compared to lumpectomy alone. Certain factors increase the risk of recurrence, including higher nuclear grade, large size, age less than 50, and close margins. RTOG 9804 demonstrated a reduction in local failure after WBRT with the use of adjuvant radiation in women with "good-risk disease" (mammographically detected, measuring less than or equal to 2.5 cm, with a predominant nuclear grade of 1 or 2, and a margin of greater than or equal to 1 cm, or a negative re -excision). The purpose of this study is to retrospectively identify the patterns of care in women with low-risk DCIS utilizing the National Cancer Database (NCDB). We hypothesize that with the utilization of hypofractionation, there may be an increase in the delivery of RT for these "good-risk" patients.Materials/methods The National Cancer Database was queried to identify women treated with lumpectomy for <2.5 cm, nuclear grade 1 or 2 DCIS of the breast from 2004 to 2016. Data were collected regarding age, tumor size, endocrine therapy use, ER receptor status, race, insurance type, and distance from the treatment center. The distance was stratified into quartiles consisting of 0-3.9, 4-8, 8.1-15.8, and > 15.8 miles, respectively. Radiation fractionation was collected and categorized as hypofractionation, standard fractionation, or other if fractionation could not be ascertained. Clinical and patient-related factors were compared between patients who received radiation and those who received no radiation. The frequency distributions between categorical variables were compared using the Chi-square test. Multivariable logistic regression was used to identify covariables that impacted the receipt of radiation.Results The eligibility criteria were met by a total of 12,846 patients. Of those, 6,600 (51.4%) received adjuvant WBRT. On multivariable regression, patients whose tumors were ER (OR 1.24, P<0.001) and those who had not received endocrine therapy (OR 2.24, P<0.001) were more likely to receive WBRT. Factors less likely to receive WBRT included increasing age over 50 (age 50-65 OR 0.83, P<0.001; age>65 OR 0.58, P<0.001), and distance of >15.8 miles (OR 0.78, P<0.001). The fractionation technique was categorized as standard or hypofractionated in 52.2% of patients. Of those, the use of hypofractionation increased from 0.4% in 2004 to 8.9% in 2010 and to 53.8% in 2016.Conclusion This NCDB analysis demonstrated that patients who meet the RTOG 9804 criteria for "good-risk" DCIS are less likely to receive RT as time progresses despite an increase in the utilization of hypofractionation techniques. Overall, slightly more than half of these patients receive adjuvant RT.
引用
收藏
页数:7
相关论文
共 27 条
  • [1] Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
    Allred, D. Craig
    Anderson, Stewart J.
    Paik, Soonmyung
    Wickerham, D. Lawrence
    Nagtegaal, Iris D.
    Swain, Sandra M.
    Mamounas, Elefetherios P.
    Julian, Thomas B.
    Geyer, Charles E., Jr.
    Costantino, Joseph P.
    Land, Stephanie R.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) : 1268 - 1273
  • [2] [Anonymous], 2022, NAT COMPR CANC NETW
  • [3] A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
    Bremer, Troy
    Whitworth, Pat W.
    Patel, Rakesh
    Savala, Jess
    Barry, Todd
    Lyle, Stephen
    Leesman, Glen
    Linke, Steven P.
    Jirstrom, Karin
    Zhou, Wenjing
    Amini, Rose-Marie
    Warnberg, Fredrik
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (23) : 5895 - 5901
  • [4] Recent Trends in Breast Cancer Among Younger Women in the United States
    Brinton, Louise A.
    Sherman, Mark E.
    Carreon, J. Daniel
    Anderson, William F.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (22): : 1643 - 1648
  • [5] Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
    Brunt, Adrian Murray
    Haviland, Joanne S.
    Wheatley, Duncan A.
    Sydenham, Mark A.
    Alhasso, Abdulla
    Bloomfield, David J.
    Chan, Charlie
    Churn, Mark
    Cleator, Susan
    Coles, Charlotte E.
    Goodman, Andrew
    Harnett, Adrian
    Hopwood, Penelope
    Kirby, Anna M.
    Kirwan, Cliona C.
    Morris, Carolyn
    Nabi, Zohal
    Sawyer, Elinor
    Somaiah, Navita
    Stones, Liba
    Syndikus, Isabel
    Bliss, Judith M.
    Yarnold, John R.
    [J]. LANCET, 2020, 395 (10237) : 1613 - 1626
  • [6] Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
    Coles, Charlotte E.
    Griffin, Clare L.
    Kirby, Anna M.
    Titley, Jenny
    Agrawal, Rajiv K.
    Alhasso, Abdulla
    Bhattacharya, Indrani S.
    Brunt, Adrian M.
    Ciurlionis, Laura
    Chan, Charlie
    Donovan, Ellen M.
    Emson, Marie A.
    Harnett, Adrian N.
    Haviland, Joanne S.
    Hopwood, Penelope
    Jefford, Monica L.
    Kaggwa, Ronald
    Sawyer, Elinor J.
    Syndikus, Isabel
    Tsang, Yat M.
    Wheatley, Duncan A.
    Wilcox, Maggie
    Yarnold, John R.
    Bliss, Judith M.
    [J]. LANCET, 2017, 390 (10099) : 1048 - 1060
  • [7] Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy - Results from the Nurses' Health Study
    Collins, LC
    Tamimi, RM
    Baer, HJ
    Connolly, JL
    Colditz, GA
    Schnitt, SJ
    [J]. CANCER, 2005, 103 (09) : 1778 - 1784
  • [8] Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
    Cuzick, Jack
    Sestak, Ivana
    Pinder, Sarah E.
    Ellis, Ian O.
    Forsyth, Sharon
    Bundred, Nigel J.
    Forbes, John F.
    Bishop, Hugh
    Fentiman, Ian S.
    George, William D.
    [J]. LANCET ONCOLOGY, 2011, 12 (01) : 21 - 29
  • [9] Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
    Darby S.
    McGale P.
    Correa C.
    Taylor C.
    Arriagada R.
    Clarke M.
    Cutter D.
    Davies C.
    Ewertz M.
    Godwin J.
    Gray R.
    Pierce L.
    Whelan T.
    Wang Y.
    Peto R.
    Albain K.
    Anderson S.
    Barlow W.
    Bergh J.
    Bliss J.
    Buyse M.
    Cameron D.
    Carrasco E.
    Coates A.
    Collins R.
    Costantino J.
    Cuzick J.
    Davidson N.
    Davies K.
    Delmestri A.
    Di Leo A.
    Dowsett M.
    Elphinstone P.
    Evans V.
    Gelber R.
    Gettins L.
    Geyer C.
    Goldhirsch A.
    Gregory C.
    Hayes D.
    Hill C.
    Ingle J.
    Jakesz R.
    James S.
    Kaufmann M.
    Kerr A.
    MacKinnon E.
    McHugh T.
    Norton L.
    Ohashi Y.
    [J]. LANCET, 2011, 378 (9804) : 1707 - 1716
  • [10] SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening
    Emdin, Stefan O.
    Granstrand, Bengt
    Ringberg, Anita
    Sandelin, Kerstin
    Arnesson, Lars-Gunnar
    Nordgren, Hans
    Anderson, Harald
    Garmo, Hans
    Holmberg, Lars
    Wallgren, Arne
    [J]. ACTA ONCOLOGICA, 2006, 45 (05) : 536 - 543